A Double-Arm, Multicenter, Phase II Clinical trial of Bone Healing Accelerant in Open Tibia Fractures
Latest Information Update: 06 Dec 2023
At a glance
- Drugs CT 101-carmell corporation (Primary)
- Indications Fracture
- Focus Proof of concept; Registrational; Therapeutic Use
- Acronyms HEAL I
- Sponsors Carmell Corporation; Carmell Therapeutics
Most Recent Events
- 30 Apr 2020 New trial record
- 27 Apr 2020 According to a Carmell Therapeutics media release, Carmell Therapeutics is now on a path to be the first company in the bone healing space with a BLA supported by two prospective, randomized, multicenter clinical studies demonstrating superiority to the current standard of care.
- 27 Apr 2020 According to a Carmell Therapeutics media release, Carmells Bone Healing Accelerant (CT-101) is regulated under the U.S. FDAs Center for Biologics Evaluation and Research. The FDA accepted the data and the overall study design from this double-arm, multicenter, Phase II clinical trial of Bone Healing Accelerant in open tibia fractures.